Private Asset Management Inc. cut its holdings in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 97.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 720 shares of the specialty pharmaceutical company’s stock after selling 33,280 shares during the quarter. Private Asset Management Inc.’s holdings in Adamas Pharmaceuticals were worth $720,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Tower Research Capital LLC TRC bought a new stake in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $109,000. American International Group Inc. boosted its position in Adamas Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock valued at $180,000 after acquiring an additional 682 shares in the last quarter. Virtu KCG Holdings LLC bought a new stake in Adamas Pharmaceuticals during the 2nd quarter valued at approximately $184,000. Wells Fargo & Company MN boosted its position in Adamas Pharmaceuticals by 28.4% during the 1st quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock valued at $266,000 after acquiring an additional 3,358 shares in the last quarter. Finally, Alps Advisors Inc. boosted its position in Adamas Pharmaceuticals by 6.7% during the 2nd quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock valued at $353,000 after acquiring an additional 1,272 shares in the last quarter. 71.95% of the stock is currently owned by institutional investors.
Shares of Adamas Pharmaceuticals, Inc. (ADMS) traded up 3.54% during mid-day trading on Friday, hitting $19.32. The stock had a trading volume of 251,401 shares. The company’s 50 day moving average is $20.74 and its 200-day moving average is $17.85. Adamas Pharmaceuticals, Inc. has a 52-week low of $12.10 and a 52-week high of $24.18. The stock’s market cap is $434.97 million.
Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter in the previous year, the company posted ($0.78) EPS. The business’s quarterly revenue was down 90.9% on a year-over-year basis. On average, equities research analysts anticipate that Adamas Pharmaceuticals, Inc. will post ($3.77) earnings per share for the current fiscal year.
Several analysts have weighed in on the company. ValuEngine raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a research report on Wednesday, September 20th. Zacks Investment Research cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, William Blair reaffirmed an “ourperform” rating on shares of Adamas Pharmaceuticals in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $39.50.
COPYRIGHT VIOLATION WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Holdings Trimmed by Private Asset Management Inc.” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/private-asset-management-inc-trims-position-in-adamas-pharmaceuticals-inc-adms.html.
Adamas Pharmaceuticals Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.